LAYLAA 21 100 MCG
LEVONORGESTREL : 100 MCG ETHINYL ESTRADIOL : 20 MCG · DIN 02424282 · LUPIN PHARMA CANADA LIMITED
Health Canada status: MARKETED
What is LAYLAA 21?
LAYLAA 21 100 MCG contains LEVONORGESTREL : 100 MCG ETHINYL ESTRADIOL : 20 MCG. It is listed in the Health Canada Drug Product Database under DIN 02424282, held by LUPIN PHARMA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Nov-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LAYLAA 21 used for?
Conception control. Treatment of moderate acne vulgaris in women >14 years of age who desire contraception and have achieved menarche.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02424282 |
|---|---|
| Brand name | LAYLAA 21 |
| Generic / active ingredient | LEVONORGESTREL : 100 MCG ETHINYL ESTRADIOL : 20 MCG |
| Manufacturer | LUPIN PHARMA CANADA LIMITED |
| Strength | 100 MCG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AA07 LEVONORGESTREL AND ESTROGEN |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Nov-2023 |
| Original market date | 2023-07-06 00:00:00 |
How is it administered?
One tablet daily. LAYLAA 21: 21 days on, 7 days off. LAYLAA 28: 21 pink active tablets followed by 7 white inert tablets. Take at the same time daily, preferably evening or bedtime.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11 of full monograph).
How is it supplied?
Blister packs. LAYLAA 21 contains 21 pink tablets. LAYLAA 28 contains 21 pink active tablets and 7 white inert tablets.
Contraindications
Hypersensitivity; history of thromboembolic disorders, CVD, MI, PVD; migraines with aura; active liver disease; breast/estrogen-dependent cancer; undiagnosed vaginal bleeding; pregnancy; hypertension.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular effects, especially in women >35. Does not protect against STIs/HIV. Increased risk of VTE, stroke, and MI.
What can be used instead?
Other Canadian products sharing ATC code G03AA07 LEVONORGESTREL AND ESTROGEN. 18 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALESSE 21 | 100 MCG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02236974 |
| ALESSE 28 | 20 MCG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02236975 |
| ALYSENA 21 | 20 MCG | TABLET | APOTEX INC | MARKETED | DIN 02387875 |
| ALYSENA 28 | 20 MCG | TABLET | APOTEX INC | MARKETED | DIN 02387883 |
| AUDRINA 21 | 100 MCG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02532174 |
| AUDRINA 28 | 100 MCG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02532182 |
| AVIANE 21 | 20 MCG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02298538 |
| AVIANE 28 | 100 MCG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02298546 |
| INDAYO | 0.03 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02398869 |
| LAYLAA 28 | 20 MCG | TABLET | LUPIN PHARMA CANADA LIMITED | MARKETED | DIN 02424290 |
Who else supplies LEVONORGESTREL AND ESTROGEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVONORGESTREL AND ESTROGEN appears in 18 registered pack listings across 3 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.